FLEMINGTON, N.J., June 19, 2012 (GLOBE NEWSWIRE) -- Beardsworth announces the appointment of Charles 'Bud' Preston as Chief Operating Officer and the promotion of Patrick J. Mancini to Chief Financial Officer.
Photos accompanying this release are available at
http://www.globenewswire.com/newsroom/prs/?pkgid=13321
http://www.globenewswire.com/newsroom/prs/?pkgid=13322
Bud Preston has an impressive track record in the clinical research industry having served as Senior Director, Clinical Operations for ViroPharma Incorporated as well as Summit Drug Development Services and Sanofi Research, a division of Sanofi Pharmaceuticals.
"With more than 20 years in the clinical research industry, Bud brings significant leadership and scientific experience, along with a strong sense of commitment to clinical trial excellence and customer satisfaction, to the Beardsworth team," said Douglas Beardsworth, Principal and Executive Chairman of Beardsworth.
As Chief Operating Officer, Bud Preston will head Beardsworth's clinical operations and administrative departments. "I am honored in the trust and confidence shown to me and am excited to take the helm as Beardsworth begins its next 25 years. The increasing demands of our industry require the very best service that we can provide and I am proud to lead this talented organization."
Patrick Mancini, Chief Financial Officer, joined Beardsworth in 2003 and has held roles of increased responsibility including Controller & Business Solutions Manager, Finance Manager, and Operations Analyst. His hands-on experience with the integration and development of business proposals, customized business models, and contract negotiation provides him with an in-depth understanding the CRO industry and client requirements.
"Combining these promotions with our existing senior management team, I am confident that we have the optimal team in place to provide our clients with the best stewardship of their clinical trials and provide for the future growth of the company," said Mr. Beardsworth.
Beardsworth accepted the resignation of Michael J. O'Brien who served the company for the past 10 years, most recently as President & CEO. "We are extremely grateful to Michael for many years of service, leadership and dedication to Beardsworth and wish him well in his future endeavors," stated Mr. Beardsworth.
Beardsworth is a specialty CRO providing full-service, business solutions for complex/rescue clinical trials with particular expertise in oncology, vaccine technologies, and supportive care. Beardsworth's team of professionals averages 20+ years of experience from clinical trial design, conduct, management, safety and reporting through FDA approval. The company's Investigator Express and Site Ambassador Program are key programs for site feasibility and optimal trial implementation. Beardsworth's OncologyOne® delivers complete business and research strategies for global trials. Experienced with government contracting, Beardsworth is a federal CCR registrant and designated Small Business.
The Beardsworth Consulting Group logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13320
